EU patent for AstraZeneca's Symbicort in COPD revoked
A week after submitting its combination asthma drug Symbicort to be marketed in the USA as a treatment for chronic obstructive pulmonary disease, the firm has been told that its patents for that indication in Europe are no longer valid

Read more ...